What Is CJC-1295?
CJC-1295 (CJC-1295 DAC) is classified as a ghrh analog peptide. Stimulates prolonged GH and IGF-1 release by mimicking the body's natural GHRH signal to the pituitary gland. Preserves natural pulsatile GH release pattern.
It is extensively evaluated in laboratory and clinical settings for its potential to drive muscle growth, fat loss, recovery. Researchers target CJC-1295 for its ability to interact with specific cellular and molecular pathways, making it a compound of significant interest across multiple therapeutic domains.
Often stacked with Ipamorelin; injection site reactions possible. Not FDA-approved.
How Does CJC-1295 Work?
Stimulates prolonged GH and IGF-1 release by mimicking the body's natural GHRH signal to the pituitary gland. Preserves natural pulsatile GH release pattern.
At the molecular level, CJC-1295 operates through pathways characteristic of the GHRH Analog class. By interacting with target receptors and downstream signaling cascades, the compound initiates biological responses associated with muscle growth, fat loss, recovery.
Expected Research Timeline
Weeks 2–4
Elevated energy and faster post-workout recovery; mild water retention
Months 2–3
Measurable lean mass improvements; visible fat redistribution; IGF-1 elevation confirmed on bloodwork
Long-Term
Sustained GH axis support; anti-aging body composition benefits; improved bone density over 6+ months
What Does the Research Say?
The following are key findings from peer-reviewed studies on CJC-1295, indexed on PubMed and equivalent databases:
[1]CJC-1295 GH/IGF-1 elevation in humans
Teichman et al. (J. Clin. Endocrinol. Metab.): Single injection increases GH 2-10x for 6+ days and IGF-1 1.5-3x for 9-11 days in healthy adults. Well-tolerated at 30-60 µg/kg.
Evidence: moderate[2]CJC-1295 preserves pulsatile GH secretion in humans
Ionescu & Bhatt (J. Clin. Endocrinol. Metab.): Demonstrates 7.5-fold increase in basal GH, 46% increase in mean GH, and 45% increase in IGF-1 while preserving natural pulsatile pattern.
Evidence: moderate[3]Long-acting GHRH analogs increase pituitary GH mRNA
Animal study shows CJC-1295 increases total pituitary RNA and GH mRNA, suggesting proliferation of somatotroph cells for sustained GH production.
Evidence: preclinicalSafety & Side Effects
Often stacked with Ipamorelin; injection site reactions possible. Not FDA-approved.
| Side Effect | Incidence | Severity |
|---|---|---|
| Water retention | ~15% of users | mild |
| Headache / GH flush | ~8% of users | mild |
| Injection site reaction | ~5% of users | mild |
| Temporary fatigue | ~5% of users | mild |
FDA Status: Not Approved for Human Therapeutic Use
CJC-1295 is not currently FDA-approved for human use. It is available for research purposes only. Always consult a licensed healthcare provider.
How Is CJC-1295 Used?
Route
SubQ
Dose Range
1000–1000 mcg
Frequency
3x/week
Cycle
8–8 wk
Timing: Pre-bed or morning fasted
Notes: CJC-1295 DAC version has 7-day half-life. Mod GRF 1-29 (no DAC) has ~30min half-life.
All dosing information reflects parameters reported in published research literature and is not intended as clinical guidance. Usage of any peptide should be supervised by a qualified healthcare professional.
CJC-1295 vs. Related Compounds
| Compound | Primary Use |
|---|---|
| CJC-1295(this page) | Muscle growth, fat loss, recovery |
| Ipamorelin | GH release, muscle growth, recovery without cortisol spike |
| Sermorelin | Muscle growth, recovery, sleep, anti-aging |
| Tesamorelin | Visceral fat reduction, body recomposition |
Where to Source CJC-1295 for Research
Purchasing ultra-high purity, laboratory-grade peptides is critical for verifiable research. We only recommend vendors providing independent, third-party HPLC Certificates of Analysis (COA).
Disclosure: PeptiDex may earn a commission from purchases. This does not affect our recommendations. We exclusively feature vendors that pass our strict quality verification protocols.
Frequently Asked Questions
What is CJC-1295?
CJC-1295 is a ghrh analog peptide. Stimulates prolonged GH and IGF-1 release by mimicking the body's natural GHRH signal to the pituitary gland. Preserves natural pulsatile GH release pattern.
What are the primary research benefits of CJC-1295?
Published research identifies primary mechanisms targeting: Muscle growth, fat loss, recovery. These findings come from 3+ peer-reviewed studies indexed in our database.
What is the half-life of CJC-1295?
In published pharmacokinetic data, CJC-1295 demonstrates a half-life of approximately 168 hours.
Is CJC-1295 FDA approved?
CJC-1295 is not currently FDA-approved for human therapeutic use. It is classified as a research compound and is studied under investigational protocols. Always consult a healthcare provider.
What are common side effects of CJC-1295?
Reported side effects in published literature include Water retention (~15% of users), Headache / GH flush (~8% of users), Injection site reaction (~5% of users), Temporary fatigue (~5% of users). Most are classified as mild in severity.
How is CJC-1295 administered?
In research settings, CJC-1295 is typically administered via SubQ. CJC-1295 DAC version has 7-day half-life. Mod GRF 1-29 (no DAC) has ~30min half-life.
Sources
- CJC-1295 GH/IGF-1 elevation in humans. View on PubMed
- CJC-1295 preserves pulsatile GH secretion in humans. View on PubMed
- Long-acting GHRH analogs increase pituitary GH mRNA. View on PubMed